Current position

Pat Dorsey’s Royalty Pharma Plc (RPRX) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Dorsey Asset Management LLCVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2025Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares2.46MHighest verified quarter-end share count
Quarters reported4Verified quarters with shares above zero
What happened?

Dorsey Asset Management LLC first reported Royalty Pharma Plc in Q3 2025. The reported position was increased and reduced across later filings. Dorsey Asset Management LLC currently reports 2.46M shares. The latest verified filing showed: Bought 7.9% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 7.9% more+179.96K shares · 2.46M shares reported after the change
Filing context

Quarter-end price $56.07 · Estimated holding basis $36.89

Q1 2026
Bought 0.8% more+17.10K shares · 2.28M shares reported after the change
Filing context

Quarter-end price $47.97 · Estimated holding basis $35.38

Q4 2025
Sold 3.9% of the position−90.98K shares · 2.26M shares remained
Filing context

Quarter-end price $38.64 · Estimated holding basis $35.28

Q3 2025
New position+2.35M shares · 2.35M shares reported
Filing context

Quarter-end price $35.28 · Estimated holding basis $35.28

Portfolio importance

How important is Royalty Pharma Plc in Dorsey Asset Management LLC’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight8.8%Q2 2026
Current rank#3of 11 reported positions
Peak portfolio weight8.8%Q2 2026
Best historical rank#3Q2 2026
At peak importanceQ2 2026
RPRX
8.8%
Largest holding
16.6%
Cross-investor discovery

Who else owns Royalty Pharma Plc?

Also reported by 1 other tracked investor in their latest verified filings.

Explore Royalty Pharma Plc across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$58.412026-09-18

Market context only; not an investor transaction price.

Latest filing quarter-end price$56.07Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$36.89Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Dorsey Asset Management, LLC’s Form 13F disclosures—not Pat Dorsey’s personal brokerage account. Form 13F reports quarter-end U.S.-listed positions and certain options, but it does not reveal exact trade dates, execution prices, short positions or the purpose of an option position.